COMPETITION OF NUCLEOSIDE TRANSPORT INHIBITORS WITH BINDING OF 6-[(4-NITROBENZYL)-MERCAPTO]PURINE RIBONUCLEOSIDE TO INTACT ERYTHROCYTES AND GHOST MEMBRANES FROM DIFFERENT SPECIES

The potency of nucleoside transport inhibitors, including 6-[(4-nitrobenzyl)-mercapto]purine ribonucleoside (NBMPR), dilazep, mioflazine and its derivatives soluflazine and R57974 as inhibitors of the binding of [3H(G)]NBMPR to intact erythrocytes and respective ghost membranes from human, mouse and hamster was determined. There was no close agreement between the ic50 profiles for the different inhibitors when comparing values obtained for intact cells and membranes from each species, and there was no consistent profile of differences when considering individual drugs and comparing their actions in the three species. Present data also were compared with potency values obtained previously with the same drugs directly in nucleoside transport inhibition studies with erythrocytes from the same species as well as with [3H(G)]NBMPR binding studies in isolated liver and lung membranes from hamster. The overall conclusion from this and previous studies is that the evaluation of relative potencies in screening of potential nucleoside transport inhibitors is best carried out at the level of actual nucleoside transport studies in intact cells, since [3H(G)]NBMPR binding studies yield discrepant data. © 1990.